Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery? Review article

Article Sidebar

PDF


Published: Dec 18, 2017
DOI: https://doi.org/10.24292/01.OR.211217
Keywords:
pasiretoide, cortisol, corticotrophin, Cushing's diesease, diabets

Main Article Content

Przemysław Witek
Department of Gastroenterology, Endocrinology and Internal Diseases, Military Institute of Medicine, Warsaw
Marta Mazur
Doctoral Studies, Military Institute of Medicine, Warsaw
Joanna Witek
Department of Diabetes, Institute of Mother and Child, Warsaw

Abstract

Cushing’s disease is a rare endocrine disorder caused by ACTH-secreting pituitary adenoma. The treatment of choice is a transsphenoidal surgery performed by an experienced neurosurgeon. However, in some patients adjuvant treatment is required due to ineffective surgery or disease recurrence. This article discusses new aspects of pharmacological treatment of ACTH-dependent hypercortisolism in light of a recent publication reporting the efficacy and safety of once a month pasireotide LAR injections in Cushing’s disease

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Witek P, Mazur M, Witek J. Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?. OncoReview [Internet]. 2017Dec.18 [cited 2024May4];7(4(28):176-9. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/456
Issue
Vol 7 No 4(28) (2017)
Section
ENDOCRINOLOGY IN ONCOLOGY

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Arnaldi G, Angeli A, Atkinson BA. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602.
2. Biller BMK, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008; 93: 2454-2462.
3. Nieman LK, Biller BMK, Findling JW et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540.
4. Pivonello R. De Martino MC, Cappabianca P et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009: 94(1): 223-230. https://doi.org/10.1210/jc.2008-1533.
5. Colao A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 2012; 366(10): 914-24. https://doi.org/10.1056/NEJMoa1105743.
6. Lacroix A, Gu F, Gallardo W, Pivonello R et al. Pasireotide G2304 Study Group. Efficacy and safety of once monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 2017. PII: S2213-8587(17)30326-1. https://doi.org/10.1016/S2213-8587(17)30326-1.